New drugs approved globally in 2016: retrospect and prospectYANG Zhen-zheng, SUN You-song, XING Ai-min, KANG Yin-hua, ZHENG Xiao-nan, GU Jue-fen601-613
Study on the PRIority MEdicines in the European UnionSHAO Rong, SUN Hai-shun, YAN Jian-zhou, WANG Meng-yuan614-619
The validation of an indicator system of essential drug accessibility assessment in ChinaXI Xiao-yu, CHEN Piao-piao, MA Dan-dan, MAO Ning-ying620-625
Research on policy environment of pharmaceutical industry innovation under reform of the supply front base on American experienceYAN Jian-zhou, WANG Meng-yuan, SHAO Rong626-630
Advances in respiratory syncytial virus infection animal models for pharmacodynamic evaluation of related drugsSHAN Xiao-lei, SUN Tao, YU Chun-rong, WANG Qing-li631-634
The application prospects of provantis system Dispense module in the management of test article in non-clinical drug safety evaluationXIONG Ke-zhao, ZHANG Wen-hao, HAN Gang, DONG Yan-sheng, WANG Xiao-fei, WNAG Quan-jun635-638
Effect of fluorofenidone on inhibiting scar formation in rat cutaneous woundsXU Qi-rong, WANG Sheng-feng, LUO Li-na, DING Jin-song, ZHOU Yan-bin639-643
Research advances in mechanisms of resistance to arsenic trioxide in acute promyelocytic leukemiaJIN Bo, YANG Kun-peng, ZHOU Jin644-647
Clinical observation study of butyphthalide for massive cerebral infarctionLIN Ya-nan, ZHANG Ya, WANG Yu, YU Ruo-mei, GUO Yan, SUN Xiao-pei656-660